GentiBio develops engineered regulatory T cells (Tregs) using a proprietary autologous and allogeneic platform that integrates complementary technologies to (re)establish immune tolerance and address limitations of existing Treg therapeutics. The company is advancing programs across autoimmune, alloimmune, autoinflammatory and allergic diseases, with a particular focus on a potential functional cure for Type 1 Diabetes (T1D). GentiBio is currently selecting its clinical candidate for T1D and plans to begin IND-enabling studies before the end of the year. It intends to use the $157M Series A financing to advance the T1D program to the clinic alongside multiple other pipeline programs in chronic autoimmunity and autoinflammation. The company launched in August 2020 and raised $20M in seed funding from OrbiMed, Novartis Venture Fund and RA Capital. GentiBio is led by President and CEO Adel Nada, M.D., M.S. GentiBio is a Seattle-based biotherapeutics company led by CEO Adel Nada, M.D., developing engineered regulatory T cells (EngTregs) to treat autoimmune, alloimmune, autoinflammatory and allergic diseases. Its proprietary autologous and allogeneic EngTregs platform integrates complementary technologies intended to restore immune tolerance and address limitations of existing regulatory T-cell therapeutics. The platform aims to enable scaled production of antigen-specific, tunable EngTreg cell therapy products. GentiBio has entered exclusive licensing partnerships with Seattle Children’s Research Institute, Benaroya Research Institute at Virginia Mason, and MIGAL Galilee Research Institute to advance its immune tolerance platform. Under those agreements, the partners will exclusively license unique technologies to GentiBio that overcome Treg therapeutic limitations such as rarity and plasticity of endogenous Treg populations. The company closed a $20M seed funding round to advance its platform and programs.

Total raised

$177M

Funding rounds

2

Latest round

Series A

Latest activity

Aug 2021